Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
AGIO
AGIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AGIO News
Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment
Mar 02 2026
Yahoo Finance
Commodore Capital Fully Sells Agios Pharmaceuticals Shares
Feb 23 2026
Fool
Rock Springs Capital Reduces Agios Holdings
Feb 17 2026
Fool
Agios Pharmaceuticals Q4 2025 Earnings Call Insights
Feb 12 2026
seekingalpha
Agios Pharmaceuticals Reports Q4 2025 Earnings and FDA Approval
Feb 12 2026
seekingalpha
Agios Pharmaceuticals Reports Key 2025 Financial Highlights
Feb 12 2026
Newsfilter
Agios Pharmaceuticals to Announce Q4 Earnings on February 12
Feb 11 2026
seekingalpha
Key Earnings Reports and Economic Outlook This Week
Feb 08 2026
CNBC
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
Dec 27 2025
Yahoo Finance
HC Wainwright Raises Agios Price Target to $62
Dec 26 2025
Benzinga
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
Dec 26 2025
NASDAQ.COM
Agios Receives FDA Approval for AQVESME to Treat Thalassemia
Dec 26 2025
Newsfilter
Agios Pharmaceuticals Target Price Raised 12.72% to $32.77
Dec 25 2025
NASDAQ.COM
BofA Maintains Buy Rating on Agios Pharmaceuticals with 12.72% Price Target Upside
Dec 25 2025
NASDAQ.COM
Agios Pharmaceuticals Receives FDA Approval for AQVESME, Shares Surge 18%
Dec 24 2025
Fool
Show More News
